New drug combo shows promise in shrinking head and neck tumors before surgery
NCT ID NCT07400094
First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tests a combination of an immunotherapy drug (camrelizumab) and two chemotherapy drugs (paclitaxel and carboplatin) given before surgery to people with advanced head and neck cancer. The goal is to see if this treatment can shrink or eliminate tumors before surgery, potentially improving long-term outcomes. Fifty participants will receive three cycles of the drug combo, then undergo surgery, followed by additional treatment based on what the surgery finds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNGEAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
P.A. Hertsen Moscow Oncology Research Institute
Moscow, Russia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.